Fulcrum Therapeutics and Slate Medicines Merge in $245 Million Migraine Reverse Merger

Companies: Fulcrum Therapeutics & Slate Medicines · Event Type: Reverse Merger + Private Placement · Financing: $245 Million, Led by Frazier Life Sciences · Lead Asset: SLTE-1009 (PACAP/VIP Antibody) · Indication: Migraine Prevention · Announcement Date: August 17, 2026 Summary Fulcrum Therapeutics and privately held…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Astellas / AviadoBio – Gene Therapy Program Sustained via Nonprofit Funding
Samsung Biologics Moves Into Peptide Manufacturing
Boulevard Bio Launches with $65 Million
GSK – $1B SiranBio Oligo Deal